Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Patient characteristics of the ST cohort at inclusion (N = 1174)*

From: Biosimilar filgrastim treatment patterns and prevention of febrile neutropenia: a prospective multicentre study in France in patients with solid tumours (the ZOHé study)

Characteristic Breast Lung GI: colorectal GI: non-colorectal GYN: ovarian GYN: non-ovarian Head & neck Prostate Other§ Total
n (% of total) 356 (30.3) 280 (23.9) 103 (8.8) 69 (5.9) 72 (6.3) 39 (3.3) 104 (8.9) 66 (5.6) 81 (6.9) 1174
Age, mean ± SD (years) 57.7 ± 11.9 63.9 ± 10.4 66.4 ± 11.4 63.9 ± 10.0 65.7 ± 11.6 66.2 ± 10.9 59.7 ± 11.0 71.7 ± 7.2 61.0 ± 15.6 62.3 ± 12
≥ 70 years, n (%) 57 (16.0) 76 (27.1) 37 (35.9) 22 (30.6) 30 (41.7) 18 (46.2) 16 (15.2) 37 (56.1) 29 (35.8) 322 (27.4)
Female, n (%) 351 (98.6) 87 (31.1) 45 (43.7) 26 (36.1) 72 (100) 39 (100) 15 (14.3) 0 (0) 12 (14.8) 647 (55.1)
ECOG PS, n (%) n = 354 n = 277 n = 100 n = 71 n = 68 n = 36 n = 104 n = 64 n = 79 n = 1153
 Grade 0–1 320 (90.4) 203 (73.3) 92 (92.0) 50 (70.4) 52 (76.5) 32 (88.9) 90 (86.5) 42 (65.6) 59 (74.7) 940 (81.5)
 Grade ≥ 2 34 (9.6) 74 (26.7) 8 (8.0) 21 (29.6) 16 (23.5) 4 (11.1) 14 (13.5) 22 (34.4) 20 (25.3) 213 (18.5)
Comorbidities and pathologies at risk of FN, n (%) 40 (11.2) 121 (43.2) 22 (21.4) 20 (27.8) 14 (19.4) 7 (17.9) 23 (21.9) 24 (36.4) 32 (39.5) 303 (25.8)
Stage of tumour at inclusion, n (%)
 I–IIIb 261 (73.3) 82 (29.3) 23 (22.3) 13 (18.1) 31 (43.1) 9 (23.1) 52 (49.5) 2 (3.0) 25 (30.9) 498 (42.4)
 IV 95 (26.7) 198 (70.7) 80 (77.7) 59 (81.9) 41 (56.9) 30 (76.9) 53 (50.5) 64 (97.0) 56 (69.1) 676 (57.6)
Prior G-CSF, n* (%) 43 (12.1) 46 (16.4) 5 (4.9) 7 (9.7) 14 (19.4) 7 (17.9) 12 (11.4) 13 (19.7) 23 (28.4) 170 (14.5)
Prior radiotherapy, n* (%) 81 (22.8) 77 (27.5) 19 (18.4) 10 (13.9) 9 (12.5) 18 (46.2) 44 (41.9) 35 (53.0) 14 (17.3) 307 (26.1)
Prior CT, n* (%) 107 (30.1) 105 (37.5) 47 (45.6) 29 (40.3) 37 (51.4) 17 (43.6) 35 (33.3) 51 (77.3) 26 (32.1) 454 (38.7)
Prior severe neutropenia, n* (%) 39 (11.0) 27 (9.6) 8 (7.8) 9 (12.5) 11 (15.3) 1 (2.6) 4 (3.8) 2 (3.0) 8 (9.9) 109 (9.3)
 Grade 3 14 (35.9) 18 (66.7) 4 (50.0) 3 (33.3) 6 (54.5) 1 (100) 2 (50.0) 0 (0) 1 (12.5) 49 (45.0)
 Grade 4 23 (59.0) 9 (33.3) 3 (37.5) 5 (55.6) 5 (45.5) 0 (0) 1 (25.0) 1 (50.0) 8 (100) 55 (50.5)
 Febrile 11 (28.2) 10 (37.0) 3 (37.5) 5 (55.6) 2 (18.2) 0 (0) 1 (25.0) 2 (100) 5 (62.5) 39 (35.8)
  1. *Some patients had missing data
  2. Hepatic, renal, cardiovascular, respiratory or other comorbidity (alcoholism, diabetes, hypercholesterolaemia or smoking)
  3. Febrile neutropenia was defined according to the EORTC guidelines
  4. §Other ST cohorts include urological outside prostate, sarcoma, thymic carcinoma, skin, bone, unknown primary, multiple independent sites
  5. CT chemotherapy, ECOG PS Eastern Cooperative Oncology Group performance score, FN febrile neutropenia, G-CSF granulocyte colony-stimulating factor, GI gastrointestinal, GYN gynaecological, SD standard deviation, ST solid tumour